专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明授权

US06541002B1 Compositions and methods for providing a protein to a virion 失效
标题翻译：用于向病毒体提供蛋白质的组合物和方法
公开(公告)号：US06541002B1
公开(公告)日：2003-04-01
申请号：US09281495
申请日：1999-03-30
申请人： Roger J. Pomerantz , Mohamad BouHamdan , Ling-Xun Duan , YanNing Xue
发明人： Roger J. Pomerantz , Mohamad BouHamdan , Ling-Xun Duan , YanNing Xue
IPC分类号： A61K3900
CPC分类号： C07K7/08 , A61K38/00 , C07K1/047 , C07K5/1008 , C07K5/1016 , C07K7/06 , C07K2319/00 , C12N2799/027
摘要： Compositions and methods for rendering a polypeptide capable of binding with Vpr and to susceptible to incorporation into a are provided. Methods of treating a human patient infected with a virus which expresses Vpr and methods of providing a polypeptide to a cell of a human patient are also included. The invention further includes a method of determining whether a polypeptide comprises a Vpr-binding region.
摘要翻译：提供了使能够与Vpr结合并易于掺入的多肽的组合物和方法。还包括用于治疗感染了表达Vpr的病毒的人类患者的方法和向人类患者的细胞提供多肽的方法。本发明还包括确定多肽是否包含Vpr结合区的方法。

2. 发明授权

US06251868B1 Method for treating a human immunodeficiency virus infection 失效
标题翻译：治疗人类免疫缺陷病毒感染的方法
公开(公告)号：US06251868B1
公开(公告)日：2001-06-26
申请号：US09069809
申请日：1998-04-30
申请人： Satoshi Kubota , Roger J. Pomerantz , Shigehisa Kitahara
发明人： Satoshi Kubota , Roger J. Pomerantz , Shigehisa Kitahara
IPC分类号： C07K5072
CPC分类号： A61K38/05
摘要： The present invention provides a method for preventing or treating a human immunodeficiency virus (HIV) infection, including a new or an asymptomatic infection as well as AIDS, comprising administering to a mammal in need thereof a HIV infection preventing or treating effective amount of a &ggr;-L-glutamnyl-L-cysteine ester compound of formula (I): wherein R is a straight chain, branched or cyclic hydrocarbon group having 1-10 carbon atoms, or a straight chain or branched hydrocarbon group having 1-5 carbon atoms substituted with an aromatic group; or the oxidized dimer obtained by dehydrogenation between two &ggr;-L-glutamyl-L-cysteine esters having formula (I).
摘要翻译：本发明提供了一种预防或治疗人类免疫缺陷病毒（HIV）感染的方法，包括新的或无症状的感染以及AIDS，包括向有需要的哺乳动物施用预防或治疗有效量的γ的HIV感染 -L-谷氨酰基-L-半胱氨酸酯化合物：其中R是具有1-10个碳原子的直链，支链或环状烃基或具有1-5个碳原子的直链或支链烃基取代的带有芳香族基团; 或通过在具有式（I）的两个γ-L-谷氨酰基-L-半胱氨酸酯之间脱氢获得的氧化二聚体。

3. 发明授权

US6077705A Ribozyme-mediated gene replacement 失效
标题翻译：核酶介导的基因置换
公开(公告)号：US6077705A
公开(公告)日：2000-06-20
申请号：US856331
申请日：1997-05-14
申请人： Lingxun Duan , Mark A. Zern , Roger J. Pomerantz
发明人： Lingxun Duan , Mark A. Zern , Roger J. Pomerantz
IPC分类号： A61K38/17 , A61K38/43 , A61K48/00 , C12N15/113 , C07H21/04 , C12N15/85 , C12Q1/68
CPC分类号： C12N15/113 , A61K38/57 , A61K48/00 , C12N2310/111 , C12N2310/121
摘要： Methods of gene therapy, particular ribozyme-mediated gene replacement methods, are disclosed. Method of treating patients suffering from a disease associated with expression of an abnormal form of a gene, such as alpha-1 antitrypsin mutations, are disclosed. The methods comprise the steps of administering to such a patient a nucleic acid construct encoding a ribozyme and a nucleic acid construct comprising a ribozyme resistant gene encoding a wild type form of the gene product. Recombinant vectors and pharmaceutical compositions for practicing the methods are disclosed.
摘要翻译：公开了基因治疗方法，特别是核酶介导的基因替代方法。公开了治疗患有与表达异常形式的基因例如α-1抗胰蛋白酶突变相关的疾病的患者的方法。所述方法包括以下步骤：向所述患者施用编码核酶的核酸构建体和包含编码野生型形式的基因产物的核酶抗性基因的核酸构建体。公开了用于实施该方法的重组载体和药物组合物。

4. 发明授权

US5750347A In situ polymerase chain reaction 失效
公开(公告)号：US5750347A
公开(公告)日：1998-05-12
申请号：US764538
申请日：1996-12-12
申请人： Omar Bagasra , Roger J. Pomerantz
发明人： Omar Bagasra , Roger J. Pomerantz
IPC分类号： C12Q1/68 , C07H21/04 , C12P19/34 , C12Q1/70
CPC分类号： C12Q1/6841 , C12Q1/686 , C12Q1/703
摘要： The present invention concerns in situ polymerase chain reaction and provides methods and reagents for identifying cells containing at least one selected nucleic acid sequence which may be derived from the human immunodeficiency virus.

5. 发明授权

US07226741B2 Multimerization of HIV-1 Vif protein as a therapeutic target 有权
标题翻译： HIV-1 Vif蛋白多聚化作为治疗靶点
公开(公告)号：US07226741B2
公开(公告)日：2007-06-05
申请号：US10688100
申请日：2003-10-17
申请人： Hui Zhang , Roger J. Pomerantz , Bin Yang
发明人： Hui Zhang , Roger J. Pomerantz , Bin Yang
IPC分类号： C12Q1/68
CPC分类号： C07K14/005 , A61K38/00 , C12N2740/16322 , Y10S530/826
摘要： One approach to treating individuals infected with HIV-1 is to administer to such individuals compounds that directly interfere with and intervene in the machinery by which HIV-1 replicates itself within human cells. Although the specific role of HIV-1 viral protein Vif in the viral life cycle is not known, the vif gene is essential for the pathogenic replication of lentiviruses in vivo. The present invention relates to a method for treating an individual exposed to or infected with HIV-1. Individuals identified as being exposed to or infected by HIV-1 are administered a therapeutically effective amount of one or more compounds that inhibit or prevent replication of said HIV-1 by interfering with the replicative or other essential functions of HIV-1 viral protein Vif by interactively blocking the multimerization domain of Vif, thereby preventing multimerization of Vif protein, which is important for Vif function in the lentivirus life cycle. In preferred embodiments, the compound or compounds that interactively block the multimerization domain of Vif are Vif antagonists. Pharmaceutical compositions comprising these compounds are also disclosed.
摘要翻译：治疗感染HIV-1的个体的一种方法是向这些个体施用直接干扰和干预HIV-1在人细胞内自身复制的机制的化合物。虽然HIV-1病毒蛋白Vif在病毒生命周期中的具体作用尚不清楚，但vif基因对于体内慢病毒的致病性复制至关重要。本发明涉及用于治疗暴露于或感染HIV-1的个体的方法。被鉴定为暴露于HIV-1或感染HIV-1的个体通过干扰HIV-1病毒蛋白Vif的复制或其它基本功能来抑制或阻止所述HIV-1复制的治疗有效量的一种或多种化合物交互阻断Vif的多聚化结构域，从而阻止Vif蛋白的多聚化，这对于慢病毒生命周期中的Vif功能是重要的。在优选的实施方案中，交互式阻断Vif的多聚化结构域的化合物是Vif拮抗剂。还公开了包含这些化合物的药物组合物。

6. 发明授权

US06653443B2 Multimerization of HIV-1 Vif protein as a therapeutic target 有权
标题翻译： HIV-1 Vif蛋白多聚化作为治疗靶点
公开(公告)号：US06653443B2
公开(公告)日：2003-11-25
申请号：US10118575
申请日：2002-04-08
申请人： Hui Zhang , Roger J. Pomerantz , Bin Yang
发明人： Hui Zhang , Roger J. Pomerantz , Bin Yang
IPC分类号： A61K3804
CPC分类号： C07K14/005 , A61K38/00 , C12N2740/16322 , Y10S530/826
摘要： One approach to treating individuals infected with HIV-1 is to administer to such individuals compounds that directly interfere with and intervene in the machinery by which HIV-1 replicates itself within human cells. Although the specific role of HIV-1 viral protein Vif in the viral life cycle is not known, the vif gene is essential for the pathogenic replication of lentiviruses in vivo. The present invention relates to a method for treating an individual exposed to or infected with HIV-1. Individuals identified as being exposed to or infected by HIV-1 are administered a therapeutically effective amount of one or more compounds that inhibit or prevent replication of said HIV-1 by interfering with the replicative or other essential functions of HIV-1 viral protein Vif, by interactively blocking the multimerization domain of Vif, thereby preventing multimerization of Vif protein, which is important for Vif function in the lentivirus life cycle. In preferred embodiments, the compound or compounds that interactively block the multimerization domain of Vif are Vif antagonists. Pharmaceutical compositions comprising these compounds are also disclosed.
摘要翻译：治疗感染HIV-1的个体的一种方法是向这些个体施用直接干扰和干预HIV-1在人细胞内自身复制的机制的化合物。虽然HIV-1病毒蛋白Vif在病毒生命周期中的具体作用尚不清楚，但vif基因对于体内慢病毒的致病性复制至关重要。本发明涉及用于治疗暴露于或感染HIV-1的个体的方法。鉴定为暴露于HIV-1或感染HIV-1的个体被施用治疗有效量的一种或多种化合物，其通过干扰HIV-1病毒蛋白Vif的复制或其它基本功能来抑制或阻止所述HIV-1的复制，通过交互阻断Vif的多聚化结构域，从而防止Vif蛋白的多聚化，这对于慢病毒生命周期中的Vif功能是重要的。在优选的实施方案中，交互式阻断Vif的多聚化结构域的化合物是Vif拮抗剂。还公开了包含这些化合物的药物组合物。

7. 发明授权

US5589333A In situ polymerase chain reaction 失效
标题翻译：原位聚合酶链反应
公开(公告)号：US5589333A
公开(公告)日：1996-12-31
申请号：US225491
申请日：1994-04-11
申请人： Omar Bagasra , Roger J. Pomerantz
发明人： Omar Bagasra , Roger J. Pomerantz
IPC分类号： C12Q1/68 , C07H21/04 , C12P19/34 , C12Q1/70
CPC分类号： C12Q1/6841 , C12Q1/686 , C12Q1/703
摘要： The present invention concerns in situ polymerase chain reaction and provides methods and reagents for identifying cells containing at least one selected nucleic acid sequence which may be derived from the human immunodeficiency virus.
摘要翻译：本发明涉及原位聚合酶链反应，并提供用于鉴定含有至少一种选自可能衍生自人类免疫缺陷病毒的选择的核酸序列的细胞的方法和试剂。

8. 发明申请

US20080167199A1 Multimerization of HIV-1 vif protein as a therapeutic target 有权
标题翻译： HIV-1 vif蛋白多聚化作为治疗靶点
公开(公告)号：US20080167199A1
公开(公告)日：2008-07-10
申请号：US11809953
申请日：2007-06-04
申请人： Hui Zhang , Roger J. Pomerantz , Bin Yang
发明人： Hui Zhang , Roger J. Pomerantz , Bin Yang
IPC分类号： C40B30/04 , G01N33/566 , G01N33/53
CPC分类号： C07K14/005 , A61K38/00 , C12N2740/16322 , Y10S530/826
摘要： The HIV-1 protein Vif comprises a multimerization domain that allows Vif-Vif interaction and Vif multimerization, which is important for Vif function in the HIV-1 life-cycle. A method for screening for an antagonist of Vif comprises contacting the multimerization domain of Vif with a test compound that specifically binds the multimerization domain. Antagonists identified by the screening assay inhibit Vif multimerization. The antagonists inhibit essential functions of Vif and accordingly are useful as inhibitors of HIV-1 replication.
摘要翻译： HIV-1蛋白Vif包含允许Vif-Vif相互作用和Vif多聚化的多聚化结构域，这对HIV-1生命周期中的Vif功能是重要的。筛选Vif拮抗剂的方法包括使Vif的多聚化结构域与特异性结合多聚化结构域的测试化合物接触。通过筛选测定鉴定的拮抗剂抑制Vif多聚化。拮抗剂抑制Vif的基本功能，因此可用作HIV-1复制的抑制剂。

9. 发明授权

US5763242A Method for increasing transduction efficiency of recombinant retroviral vectors 失效
标题翻译：提高重组逆转录病毒载体转导效率的方法
公开(公告)号：US5763242A
公开(公告)日：1998-06-09
申请号：US385446
申请日：1995-02-08
申请人： Hui Zhang , Roger J. Pomerantz
发明人： Hui Zhang , Roger J. Pomerantz
IPC分类号： C12N15/63 , C12N15/867 , C12N15/00 , C12N5/10 , C12N15/86
CPC分类号： C12N15/86 , C12N15/63 , C12N2740/13043
摘要： A method for improving the transduction efficiency of retroviral vectors into a host cell wherein the retroviral vectors are incubated with deoxyribonucleoside triphosphates prior to transduction into the host cell is provided.
摘要翻译：提供了将逆转录病毒载体转导入宿主细胞的转导效率的方法，其中逆转录病毒载体在转导入宿主细胞之前与脱氧核糖核苷三磷酸一起温育。

10. 发明申请

US20110086423A1 Cellular Targets for Treatment of Retroviral Infection 审中-公开
标题翻译：用于治疗逆转录病毒感染的细胞靶标
公开(公告)号：US20110086423A1
公开(公告)日：2011-04-14
申请号：US12815125
申请日：2010-06-14
申请人： Rene Daniel , Anna Marie Skalka , Gary D. Kao , Giuseppe Nunnari , Roger J. Pomerantz
发明人： Rene Daniel , Anna Marie Skalka , Gary D. Kao , Giuseppe Nunnari , Roger J. Pomerantz
IPC分类号： C12N5/071
CPC分类号： C12Q1/485 , C12Q1/18
摘要： Cellular targets for anti-retroviral drug development are disclosed. The cellular targets comprise ATR kinase and its relevant substrates, based on the identification of the ATR kinase as required for the final step of retroviral DNA integration. Assays for identifying modulators of retroviral integration via the ATR kinase pathway are disclosed, as well as modulators identified by such assays. Pharmaceutical preparations and methods of their use in treating retroviral infection are also disclosed.
摘要翻译：公开了用于抗逆转录病毒药物开发的细胞靶标。基于逆转录病毒DNA整合的最终步骤所需的ATR激酶的鉴定，细胞靶标包含ATR激酶及其相关底物。公开了通过ATR激酶途径鉴定逆转录病毒整合的调节剂的测定，以及通过这些测定法鉴定的调节剂。还公开了其用于治疗逆转录病毒感染的药物制剂及其用途。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式